



PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**

~~Substitute for form 1449/PTO~~

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

*(Use as many sheets as necessary)*

Sheet

1

of

7

**Complete if Known**

Application Number	10/623,065
Filing Date	July 18, 2003
First Named Inventor	S. Banerjee
Art Unit	1642
Examiner Name	David J. Blanchard
Attorney Docket Number	BBC-202

**U. S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup> "Number" Kind Code <sup>3</sup> (if known)				
DB		WO 02/100330	12-19-2002	Abbott Biotechnology Ltd.		
		WO 04/004633	01-15-2004	Abbott Biotechnology Ltd.		
↓		WO 04/016286	02-26-2004	Abbott Laboratories (Berm		
DB		WO 04/037205	05-06-2004	Abbott Biotechnology Ltd.		
		WO 97/29131	08-14-1997	BASF Aktiengesellschaft		

Examiner Signature	/David Blanchard/	Date Considered	09/01/2006
-----------------------	-------------------	--------------------	------------

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
				Application Number	10/623,065
				Filing Date	July 18, 2003
				First Named Inventor	S. Banerjee
				Art Unit	1642
				Examiner Name	David J. Blanchard
Sheet	2	of	7	Attorney Docket Number	BBC-202

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T <sup>2</sup>
DB		BALBAY et al. "Circulating Interleukin-1 Beta, Interleukin-6, Tumor Necrosis Factor-Alpha, and Soluble ICAM-1 in Patients with Chronic Stable Angina and Myocardial Infarction" (2001) Angiology. 52:109				
		BELOSJOROW et al. "TNF- $\alpha$ antibodies are as effective as ischemic preconditioning in reducing infarct size in rabbits" (2003) Am. J. Physiol. Heart Circ. Physiol. Mar; 284(3):H927-930.				
		BERK, BC et al. "Restenosis After Percutaneous Transluminal Coronary Angioplasty: New Therapeutic Insights From Pathogenic Mechanisms" (1995) Adv. Intern. Med., 40:455-501				
		BOZKURT et al. "Results of Targeted Anti-Tumor Necrosis Factor Therapy with Etanercept (ENBREL) in Patients with Advanced Heart Failure" (2001 Feb 27), 103(8):1044-7				
		BULT, H. "Restenosis: a challenge for pharmacology" (2000) Trends in Pharmacological Sciences, 21:274-279				
		BURNS, et al. "The Relationships of Left Ventricular Ejection Fraction, End-Systolic Volume Index and Infarct Size to Six-Month Mortality After Hospital Discharge Following Myocardial Infarction Treated by Thrombolysis" (2002) J. Am Coll Cardiol. 39:30				
		CHUNG, et al. "Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor- $\alpha$ , in Patients with Moderate-to-Severe Heart Failure" (2003 Jul 1) Circulation, 107(25):3133-40				
		CLAGETT, et al. "Morphogenesis and clinicopathologic characteristics of recurrent carotid disease" (1986) J. Vasc. Surg. 3:10-23				
↓		CLAUSELL, et al. "Expression of tumour necrosis factor $\alpha$ and accumulation of fibronectin in coronary artery restenotic lesions retrieved by atherectomy" (1995) Br. Heart J., 73(6):534-539				
DB		CLELAND, et al. "Clinical Trials Update: Capricorn, Copernicus, Miracla, Staf, Ritz-2, Recover and Renaissance and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001" (2001 Jun) Eur. J. Heart Fail., 3(3):381-387				

Examiner Signature	/David Blanchard/	Date Considered	09/01/2006
--------------------	-------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.  
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
				Application Number	10/623,065
				Filing Date	July 18, 2003
				First Named Inventor	S. Banerjee
				Art Unit	1642
				Examiner Name	David J. Blanchard
Sheet	3	of	7	Attorney Docket Number	BBC-202

<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
DB		CLOWES, et al. "Mechanisms of Stenosis after Arterial Injury" (1983) Laboratory Investigation, 49:208			
		CUSACK, et al. "Systemic Inflammation in Unstable Angina Is the Result of Myocardial Necrosis" (2002 June 19) J. Am. Coll. Cardiol. 39(12):1917-1923			
		de WAARD, et al. "Plasminogen Activator Inhibitor 1 and Vitronectin Protect Against Stenosis in a Murine Carotid Artery Ligation Model" (2002) Arterioscler. Thromb. Vasc. Biol. 22:1978-1983.			
		DESWAL, et al. "Safety and Efficacy of a Soluble P75 Tumor Necrosis Factor Receptor (Enbrel, Etanercept) in Patients With Advanced Heart Failure" (1999 Jun 29), Circulation, 99(25):3224-3226			
		FERNS, et al. "Inhibition of Neointimal Smooth Muscle Accumulation After Angioplasty by an Antibody to PDGF" (1991) Science 253:1129			
		FICHTLSCHERER, et al. "Tumor Necrosis Factor Antagonism With Etanercept Improves Systemic Endothelial Vasoreactivity in Patients with Advanced Heart Failure" (2001 Dec 18) Circulation 104(25):3023-3025			
		GUREVITCH, et al. "Anti-Tumor Necrosis Factor-Alpha Improves Myocardial Recovery After Ischemia and Reperfusion" (1997 Nov 15) J. Am Coll. Cardiol. 30(6):1554-1561			
		HALAWA, et al. "Tumor necrosis factor (TNF- $\alpha$ ) and interleukin 6 (IL-6) plasma levels in patients with acute myocardial infarction" (1999 Mar) Pol. Arch. Med. Wewn. 101(3):197-203			
DB		HERSKOWITZ, et al. "Cytokine mRNA Expression in Postischemic/Reperfused Myocardium" (1995 Feb) A. J. Pathol. 146(2): 419-428			
DB		HIRSCHL, et al. "Assessment of myocardial injury by serum tumour necrosis factor alpha measurements in acute myocardial infarction" (1996 Dec) Eur. Hear J. 17(12):1852-1859			

Examiner Signature	/David Blanchard/	Date Considered	09/01/2006
--------------------	-------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	10/623,065
				Filing Date	July 18, 2003
				First Named Inventor	S. Banerjee
				Art Unit	1642
				Examiner Name	David J. Blanchard
Sheet	4	of	7	Attorney Docket Number	BBC-202

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T <sup>2</sup>
DB		IOCULANO, et al. "Tumour Necrosis Factor Mediates E-Selectin Production and Leukocyte Accumulation In Myocardial Ischaemia-Reperfusion Injury" (1995 May) Pharmacol. Res. 31(5):281-288				
		JACKSON, et al. "β-Blockers reduce the incidence of clinical restenosis: Prospective study of 4840 patients undergoing percutaneous coronary revascularization" (2003) Am Heart J. 145:875				
		JACOBS, et al. "Tumor Necrosis Factor-α at Acute Myocardial Infarction in Rats and Effects on Cardiac Fibroblasts" (1999 Nov) J. Mol. Cell. Cardiol. 31(11):1949-1959				
		JAVED, et al. "Tumor Necrosis Factor-α Antibody Eluting Stents Reduce Vascular Smooth Muscle Cell Proliferation in Saphenous Vein Organ Culture" (2002 Oct) Exp. Mol. Pathol. 73(2):104-111				
		KUMAR, A. AND LINDNER, V. "Remodeling with Neointima Formation in the Mouse Carotid Artery After Cessation of Blood Flow" (1997) Arterioscler. Thromb. Vasc. Biol. 17:2238				
		KUMAR, et al. "Remodeling and Neointimal Formation in the Carotid Artery of Normal and P-Selectin-Deficient Mice" (1997) Circulation 96(12):4333-4342				
		KURRELMEYER, et al. "Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction" (2000 May 9) PNAS USA 97(10):5456-5461				
		LENTZ, et al. "Anticoagulant Responses to Thrombin Are Enhanced During Regression of Atherosclerosis in Monkeys" (2002) Circulation 106(7):842-846				
↓		LEVINE, et al. "Elevated Circulating Levels of Tumor Necrosis Factor in Severe Chronic Heart Failure" (1990 Jul 26) N. Engl. J. Med. 323(4):236-241				
DB		LI, et al. "Kinetics of tumor necrosis factor α in plasma and the cardioprotective effect of a monoclonal antibody to tumor necrosis factor α in a acute myocardial infarction" (1999 Jun) Am Heart J. 137(6):1145-52				

Examiner Signature	/David Blanchard/	Date Considered	09/01/2006
--------------------	-------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
				<b>Application Number</b>	10/623,065
				<b>Filing Date</b>	July 18, 2003
				<b>First Named Inventor</b>	S. Banerjee
				<b>Art Unit</b>	1642
				<b>Examiner Name</b>	David J. Blanchard
Sheet	5	of	7	Attorney Docket Number	BBC-202

<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
DB		LIBBY, PETER, MD. "Molecular Bases of the Acute Coronary Syndromes" (1995) Circulation 91:2844-2850			
		LINDNER, et al. "Mouse Model of Arterial Injury" (1993) Circ Res. 73:792			
		LISSONI, et al. "Enhanced Secretion of Tumour Necrosis Factor in Patients with Myocardial Infarction" (1992 Sep) Eur. J. Med. 1(5):277-280			
		MAEKAWA, et al. "Improved Myocardial Ischemia/Reperfusion Injury in Mice Lacking Tumor Necrosis Factor- $\alpha$ " (2002 Apr 3) J. Am. coll. Cardiol. 39(7): 1229-1235			
		MENDALL, et al. "Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease" (1997) Heart 78(3):273-277			
		MENG, et al. "The Interaction Between HSP70 and TNF- $\alpha$ Expression: A Novel Mechanism For Protection of the Myocardium Against Post-Injury Depression" (2002 May) Shock 17(5):345-353			
		NAKAMURA, et al. "Induction of Left Ventricular Remodeling and Dysfunction in the Recipient Heart Following Donor Heart Myocardial Infarction: New Insights into the Pathological Role of Tumor Necrosis Factor- $\alpha$ From a Novel Heterotopic Transplant-Coronary Ligation Model" (2003 Jan) J. Cardiol. 41(1):41-42			
		OLD, LLOYD J. "Tumor Necrosis Factor (TNF)" (1985) Science 230:630-632			
		ORREGO, et al. "Coronary angioplasty and coronary artery remodeling" (1999) Cardiologia 44(7):621-625			
DB		PUDIL, et al. "Cytokines and adhesion molecules in the course of acute myocardial infarction" (1999 Feb) Clin. Chim. Acta. 280(1-2):127-134			

Examiner Signature	/David Blanchard/	Date Considered	09/01/2006
--------------------	-------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.  
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**

<p style="text-align: center;"><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p><i>(Use as many sheets as necessary)</i></p>			
<b>Substitute for form 1449/PTO</b>			
<i>Complete if Known</i>			
		<b>Application Number</b>	10/623,065
		<b>Filing Date</b>	July 18, 2003
		<b>First Named Inventor</b>	S. Banerjee
		<b>Art Unit</b>	1642
		<b>Examiner Name</b>	David J. Blanchard
<b>Sheet</b>	<b>6</b>	<b>of</b>	<b>7</b>
		<b>Attorney Docket Number</b>	
		BBC-202	

## NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
DB		RIDKER, et al. "Elevation of Tumor Necrosis Factor- $\alpha$ and Increased Risk of Recurrent Coronary Events After Myocardial Infarction" (2000 May) Circulation 101(18):2149-2153	
		SHAMES, et al. "Ischemia Alone Is Sufficient To Induce TNF- $\alpha$ mRNA and Peptide In The Myocardium" (2002 Feb) Shock 17(2):114-119	
		SMITH, K.J. AND SKELTON, H. "Common variable immunodeficiency treated with a recombinant human IgG, tumour necrosis factor- $\alpha$ receptor fusion protein" (2001 Mar) Br. J. Dermatol. 144(3):597-600	
		SORAN, et al. "The pharmacokinetics of etanercept in patients with heart failure" (2001 Feb) 51(2):191-192	
		SQUADRITO, et al. "Tumor necrosis factor involvement in myocardial ischaemia-reperfusion injury" (1993 Jun 24) Eur. J. Pharmacol. 237(2-3):223-30	
		SUGANO, et al. "In vivo gene transfer of soluble TNF- $\alpha$ receptor 1 alleviates myocardial infarction" (2002) FASEB J 16:1421	
		SUNDELL, et al. "AGI-1067: A Multifunctional Phenolic Antioxidant, Lipid Modulator, Anti-Inflammatory and Antiatherosclerotic Agent" (2003) The J of Pharmacology & Experimental Therapeutics 305(3):1116-1123	
		TANAKA, et al. "Proliferating Arterial Smooth Muscle Cells After Balloon Injury Express TNF- $\alpha$ but Not Interleukin-1 or Basic Fibroblast Growth Factor" (1996 Jan) Arterioscler. Thromb. Vasc. Biol. 15(1):12-18	
▼		TORRE-AMIONE, et al. "Proinflammatory Cytokine Levels in Patients with Depressed Left Ventricular Ejection Fraction: A Report From the Studies of Left Ventricular Dysfunction (SOLVD)" (1996 Apr) J. Am. Coll. Cardiol. 27(5):1201-1206	
DB		VALGIMIGLI, et al. "Serum From Patients With Acute Coronary Syndromes Displays a Proapoptotic Effect on Human Endothelial Cells" (2003 Jan) Circulation 107(2):264-270	

Examiner Signature	/David Blanchard/	Date Considered	09/01/2006
-----------------------	-------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
				Application Number	10/623,065
				Filing Date	July 18, 2003
				First Named Inventor	S. Banerjee
				Art Unit	1642
				Examiner Name	David J. Blanchard
Sheet	7	of	7	Attorney Docket Number	BBC-202

<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
DB		YAMASHITA, et al. "The involvement of cytokines in the second window of ischaemic preconditioning" (2000 Oct) Br. J. Pharmacol 131(3):415-422			
		ZHOU, et al. "Effect of anti-tumor necrosis factor- $\alpha$ polyclonal antibody on restenosis after balloon angioplasty in a rabbit atherosclerotic model" (2002 Mar) Atherosclerosis 161(1):153-159			
DB		ZIMMERMAN, et al. "Lack of TNFalpha attenuates intimal hyperplasia after mouse carotid artery injury" (2002 Aug) Am. J. Physiol. Regul. Integr. Comp. Physiol 283(2): R505-512			
DB		MORELAND, et al. "Double Blind Placebo Controlled Trial of Tumor Necrosis Factor Receptor Fusion Protein (TNFR:Fc) In Active Rheumatoid Arthritis" (1996) J. Invest. Med. 44:235A			

Examiner Signature	/David Blanchard/	Date Considered	09/01/2006
--------------------	-------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.  
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.